J. Reeves

发表

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

J. Leonard, K. Kolibaba, J. Reeves, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

J. Reeves, P. Hegde, A. Ravaud, 2018, Nature Medicine.

Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.

J. Reeves, J. Hainsworth, H. Burris, 2010, Clinical lung cancer.

Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung.

J. Reeves, P. Blitzer, W. Harwin, 1995, International journal of radiation oncology, biology, physics.

Phase II Randomized Double-Blinded Study of Pracinostat in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes

Farhad, J. Reeves, M. Maris, 2017 .

Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q

J. Reeves, H. Deeg, P. Greenberg, 2007 .

Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.

C. Obasaju, J. Reeves, Michael Jones, 2012, Clinical breast cancer.

PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification.

J. Reeves, I. Flinn, J. Hajdenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

J. Reeves, J. Hainsworth, O. Hamid, 2016, Targeted Oncology.

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

J. Reeves, I. Flinn, R. Neuwirth, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial

J. Reeves, R. Motzer, T. Choueiri, 2012 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

J. Reeves, I. Flinn, R. Neuwirth, 2011 .

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.

J. Reeves, A. Ravaud, J. Hainsworth, 2021, European urology.

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

J. Reeves, B. Somer, N. Vogelzang, 2020, Clinical genitourinary cancer.

Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen.

J. Reeves, A. Lobuglio, K. Zuckerman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small-cell lung carcinoma: an analysis of 194 consecutive patients.

J. Reeves, L. Hart, P. Blitzer, 1998, American journal of clinical oncology.

Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

J. Reeves, J. Hainsworth, O. Hamid, 2015 .

Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: A Sarah Cannon Research Institute phase II trial.

J. Reeves, J. Hainsworth, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-121 Lenalidomide (CC-5013; revlimid™)-inducedred blood cell (RBC) transfusion-independence (TI) responses in low-/INT-1-risk patients with myelodysplastic syndromes (MDS): Results of the multicenter mds 002 study

J. Reeves, J. Bennett, G. Dewald, 2005 .

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

J. Reeves, Minetta C. Liu, L. Ellisen, 2021, Nature Cancer.

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy

Sung-Bae Kim, J. Reeves, C. Shimizu, 2022, JAMA oncology.

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

J. Reeves, H. Hurwitz, J. Bendell, 2014 .

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

J. Reeves, C. Porta, J. Hainsworth, 2022, The oncologist.

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors

Suzanne F. Jones, J. Reeves, H. Burris, 2021, JCO precision oncology.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

J. Reeves, H. Deeg, P. Greenberg, 2008, Blood.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

J. Reeves, P. Hegde, A. Ravaud, 2018, Nature Medicine.

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

J. Burke, J. Reeves, B. Cheson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of the sphingosine‐1‐phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma

J. Reeves, J. Hainsworth, H. Drabkin, 2017, Cancer.

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

J. Reeves, M. Maris, G. Garcia-Manero, 2020, British journal of haematology.

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

J. Reeves, M. Maris, H. Kantarjian, 2017, Cancer.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

J. Reeves, R. Motzer, T. Choueiri, 2013, The New England journal of medicine.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Roy S Herbst, Vincent Miller, Rafael Rosell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

J. Burke, J. Reeves, I. Flinn, 2021, Blood advances.

Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy.

J. Reeves, I. Flinn, B. Cheson, 2020, Blood.

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

J. Reeves, I. Flinn, R. Neuwirth, 2010 .

Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute

J. Reeves, I. Flinn, J. Hainsworth, 2012 .

Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).

J. Reeves, E. Dees, F. Ademuyiwa, 2014 .

Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.

J. Reeves, I. Flinn, R. Neuwirth, 2009 .

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.

J. Reeves, M. Danso, F. Ademuyiwa, 2016, Clinical breast cancer.

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

J. Burke, J. Reeves, B. Cheson, 2020 .

Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.

J. Reeves, I. Flinn, J. Hainsworth, 2014, Clinical lymphoma, myeloma & leukemia.

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.

J. Reeves, M. Gleave, F. Saad, 2017, The Lancet. Oncology.

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).

J. Reeves, B. Somer, H. Lenz, 2019, The oncologist.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

J. Reeves, P. Hegde, A. Ravaud, 2018, Nature Medicine.

Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

J. Reeves, I. Flinn, R. Neuwirth, 2013 .

Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.

J. Reeves, J. Bono, C. Higano, 2015 .

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

J. Reeves, B. Somer, H. Lenz, 2016 .

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).

J. Leonard, K. Kolibaba, J. Reeves, 2015, Clinical advances in hematology & oncology : H&O.

A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY

J. Reeves, I. Flinn, B. Cheson, 2019, Hematological Oncology.

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy

J. Reeves, I. Flinn, J. Essell, 2017, British journal of haematology.

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

J. Burke, J. Reeves, P. Venugopal, 2021, Blood.

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.

J. Reeves, J. Berlin, A. Biankin, 2020 .

A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).

J. Reeves, P. Philip, J. Nemunaitis, 2016 .

A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R)

J. Reeves, J. Collier, H. Thomas, 1995, Journal of clinical psychopharmacology.

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.

J. Reeves, M. Danso, F. Ademuyiwa, 2016, Clinical Breast Cancer.

Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

J. Burke, K. Kolibaba, J. Reeves, 2019, Journal of Clinical Oncology.

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

J. Reeves, A. Tolcher, Dajun Yang, 2023, Journal of Clinical Oncology.